IT systems · Practical guide

Proalpha ERP for GxP: batches, interfaces and validation

Proalpha can connect purchasing, warehousing, production and quality. Which decisions does your installation actually control? Trace permitted material use, the batch consumed and the inspection status available to production across the ERP, extensions and connected systems. Use this scope to assess supplier claims and plan local tests. The product name alone does not establish GxP suitability.

Table of contents

At a glance

What do you need to validate in Proalpha for GxP use?

Assess whether the Proalpha configuration is suitable for your intended GxP processes. Focus on critical master data, batch relationships, material status, roles and transfers to quality or manufacturing systems. The effects of a possible failure determine test scope and depth. Supplier information can help but does not establish that your configuration enforces blocks or is ready for release.

  • Product name, release, modules, enhancements, and interfaces to be separately inventoried.
  • Demonstrate traceable batch numbers and an effective material usage block separately.
  • Apply MedTech-Suite features only to the validated variant and the agreed functional scope.
  • Bring together the functional areas, quality assurance, IT, and system partners prior to test planning.

Which Proalpha is intended?

Proalpha is currently offered as an ERP system for the mid-market within the Proalpha Business Application Suite. A publicly documented reference version is Proalpha ERP 9.5: the manufacturer's notification dated 25 June 2025 highlights the integration of Proalpha MES and CAQ. However, neither the version status of an existing installed system nor the latest available maintenance version has been established.

Maintain for your project ERP release and build, database, operating model, installed modules, and customer-specific enhancements. Include version details of connected systems and responsibility assignments for each integration. An ERP upgrade alone does not indicate whether an older report, a partner extension, or an independent quality process continues to function unchanged.

Proalpha also addresses medical technology. This industry solution is to be distinguished from a general ERP installation and from a pharmaceutical GMP application. The practical reference case here is a company of the human medicine production, which uses ERP data for quality-relevant material and production decisions. The concrete suitability remains to be evaluated on the basis of this application.

Sources: [1] [2] [4] [6]

Define the system boundary for decisions

For computerized systems within the GMP scope, Annex 11 mandates a risk-based approach. Therefore, the key consideration is not the number of screen layouts within the ERP, but rather whether any erroneous information could compromise product quality, patient safety, or data integrity. Purely administrative functions may fall outside the defined scope; shared master data and interconnections must be taken into account.

Begin with three real-world workflows: material receipt, material usage, and traceability of a quality issue. Identify where a technical or operational decision is made, in which system it is recorded, and the subsequent actions that follow. Include exception pathways for storage and production: manual corrections, special withdrawals, returns, and bookings following a failure.

The following work matrix assists in project scoping. It describes relevant project questions, not predefined standard functions of Proalpha. For each critical decision, a responsible party should subsequently confirm the expected state and the measurable acceptance criteria.

Decision matrix: System boundary and required evidence
DecisionIn the project to be clarifiedSubstantiated evidence
Use materials Where is the release status generated, and which booking pathways must account for it? Permitted use succeeds; unauthorized use fails or is prevented through the approved alternative procedure.
Assign the batch Which external and internal identifiers link incoming materials, partial batches, and consumption? The actual material pathway can be reconstructed in both forward and backward directions.
Use a recipe or bill of materials Which approved version applies to which order? The amended and previous version remain distinguishable; the order utilizes the intended version.
Accept quality results Which system determines which message carries the status? Faulty or outdated transfer leads to a detectable, controlled condition.
Assess the historical process trajectory What data and relationships must be available throughout the retention period? Dataset, meaning, and associated evidence remain retrievable and readable.

Sources: [6]

Verify batch traceability and material release separately.

The manufacturer describes origin and usage documentation for batch-tracked products within the return management process. This function serves as a key foundation for traceability. However, it still does not confirm whether your system reliably excludes a locked batch from usage at any relevant point.

Distinguish between batch identity, storage location, inventory quantity, and business status. A change of storage location must not inadvertently lift a block; a new internal batch key must retain its relationship to the supplier's batch. For partial quantities, specify whether a decision applies to the entire batch or only to a clearly defined inventory portion. Additionally, verify units, rounding, and the significance of cancellation or correction entries.

Do you require more than a convincing screen display for traceability reports? Are the selected time periods, filters, and linkages aligned with the investigated event? Are delivered, recalled, and already consumed quantities appropriately captured? A report can only serve as a sound basis for decision-making when its technical scope is understood and validated through appropriate examples.

Sources: [3] [6]

ERP, CAQ, and MES: Who owns which status?

Proalpha states that for Release 9.5, integration of MES and CAQ, along with open interfaces for existing systems, is included. However, no general conclusions can be drawn regarding the components, message formats, or automated error handling licensed by you. These details must be derived from your architecture and version-specific specifications.

Determine a leading system for each information. Quality management can, for example, make a material decision, while the ERP implements its effect in the warehouse. Then, the requirement also includes what happens if there is no transfer. A technical acknowledgement of receipt is not equivalent to a technically correctly assigned decision.

Plan testing for incorrect batch identifiers, duplicate messages, delayed deliveries, and interrupted processing. Particularly insightful is the sequence: what happens when, after a current block, an older release notification arrives? Define expected behavior, visible error indications, responsible parties, and retry actions prior to testing. A custom-developed interface, a report, and a standard connection may each require distinct validation evidence.

Sources: [2] [6]

Further reading:

What the MedTech Suite occupies – and what you must demonstrate

The official medical device website lists Audit Trail, electronic signature, integrated document management, and workflow-driven control. Additional functional modules cover the product lifecycle, suppliers, quality management, and production, including testing, CAPA, and batch and serial number management. These represent industry offerings; they do not indicate identical functionality across all Proalpha-ERP systems.

Please specify the required functions, product component, version, license scope, and relevant configuration in detail. The German manufacturer's side explicitly assigns specific validation to the customer and their processes. Therefore, broad marketing statements on an international product page neither substitute a customer's requirements review nor a formally approved validation evidence. Functions announced for the future must not be assumed to be available or implemented.

For critical changes, determine who is authorized to modify specific values, establish the resulting audit trail, and define how this trail is evaluated. In relation to electronic release, it is necessary to clarify identity, intent, and linkage to the released dataset. A workflow action or user name alone does not constitute an appropriate electronic signature. Part 11 should be assessed based on the affected electronic records and underlying FDA requirements, not based on ERP marketing activities.

Sources: [4] [5] [6] [7]

Migration: Significance and Relationships Maintained

During an introduction or replacement, the number of imported data sets alone is insufficient as evidence of a successful migration. Annex 11 also addresses the retention of value and significance of transferred data. For the project this means: Define what constitutes a historical status within the new system and how open activities are to be continued and processed following the system change.

Compile a manageable, purposefully selected sample size: one released and one blocked batch, partial consumption, return, corrected booking, and an open quality investigation. Compare alongside key identifiers and quantities, including relationships, date significance, units, and origin. Determine whether historical change records are retained or provided through a separate, readable legacy system.

For the transition, you require a coordinated cut-off date, rules for interim changes, a data reconciliation, and a decision on deviations. Document which data actually migrates and which continues to be retained at a different location. A tested import does not substitute for planned retention; a database backup does not constitute evidence that historical activities remain professionally interpretable.

Sources: [6]

Further reading:

Test case: a batch is blocked after the original decision

This example serves as a quality planning reference; it does not describe a completed Proalpha review. A manufacturer uses approved packaging material. Following a quality investigation, the batch is placed on hold. Part of the batch is in inventory, while another portion has been assigned to a production order. The decision is made within an integrated quality management system.

Prior to execution, Quality Assurance, Storage, and Production jointly determine which uses must be prohibited and how previously consumed material shall be assessed. The test environment must adequately replicate the relevant roles, configurations, and messaging pathways. The following matrix provides potential test ideas; specific acceptance criteria will follow your approved requirements.

Example: Test matrix for lock status and traceability
TriggerObserved effectSuitable evidence
Release is authorized. The approved normal process operates with the intended role. Originating data, booking and associated status.
The block is carried over. The professionally prohibited sampling routes are blocked or securely controlled. Status transition and attempts via all relevant routes.
The interface becomes unavailable A defined safe state and a designated responsible person prevent uncontrolled use. Error notification, handling, and operational backup justification.
Old batch release is later confirmed. The current system lockout decision is not inadvertently overridden. Message sequence and resulting material status.
Unauthorized user attempts modification The unauthorized action remains without impact on the process. Roll position, input attempt, and visible result.
Trace the affected batch Used and existing partial quantities are traceable and assignable. Comparison of the report with pre-prepared reference processes.

Sources: [6]

What a small and medium-sized enterprise should prepare and what effort it entails

Assign a process owner with decision-making authority, a responsible quality assurance function, an IT owner, and the dedicated system partner. Small companies may consolidate roles; however, responsibilities for technical requirements, implementation, and batch release must remain clearly defined. Allocate time for personnel who are familiar with exceptions and actual booking workflows.

To ensure a robust project launch, five key documents are recommended: process flowchart, system inventory, list of critical data, role overview, and list of open issues. Supplement these with available supplier or partner specifications, configuration proofs, and test results. Assess their alignment with the intended version and usage prior to adoption. A publicly committed, complete validation package is not required for Proalpha.

The main effort stems from unclear status rules, numerous interfaces, individual programs, poorly understood legacy data, and insufficient departmental time. A small system with complex exceptions may require more clarification than a larger, well-standardized setup. In the plan, separate functional clarification, technical correction, test execution, and deviation handling. Only after this separation can a reliable scheduling and budgeting process be established.

Sources: [6]

Release and operation as a continuous chain of evidence

Before use, requirements, risk assessment, configuration, and results must be aligned. Open deviations require documented evaluation and decision. Release specifies the actually reviewed scope; a list of completed tests without reference to requirements remains difficult to trace.

Annex 11 covers, among other aspects, change control, periodic evaluation, security and recovery, as well as operational continuity. Derive an operational procedure aligned with your ERP: Who evaluates release notices, who reviews a modified interface, and who tracks failed messages? Assign incidents to a designated responsible party and maintain linkage to corrections and subsequent re-evaluations.

Following changes, assess the affected functions and their interdependencies. A modified batch report may impact traceability decisions; a role change may invalidate a previously effective segregation. During restoration, in addition to technical availability, clarify how bookings from the downtime period will be reconciled. A blanket annual full-system testing program cannot be derived from this.

Sources: [6]

Checklist for the next project step

Use this work aid prior to a coordination meeting with the system partner and quality assurance. Unclear points should first be translated into specific action items. Particularly critical are missing responsibilities and unknown workarounds, as they may invalidate even well-documented individual tests later on.

  • ERP Release, Build, Module, CAQ/MES, Extensions and Interfaces to be documented with responsible parties.
  • Define the intended use and applicable GxP scope in writing.
  • Define critical batch relationships, material status and master data for the process.
  • Manual, mobile and automated booking routes relate to the same protection requirements.
  • Specify the required roles, change histories and, where applicable, electronic signatures.
  • Plan migration, historical records, and retention separately.
  • Verify manufacturer/partner certifications regarding version, scope, and traceable results.
  • Test failure cases, retry procedures, and operational contingency procedures with the responsible personnel.
  • Evaluate deviations and provide a traceable justification for the reviewed system scope.
  • Assign changes, disturbances, and periodic evaluations during ongoing operation.

Sources: [6]

Project experience and collaboration

Check whether a material decision has the intended effect

With your process owners, we follow a known batch from master data and quality status to the intended material movement. IT and the implementation partner identify the configured modules and interfaces. If an existing control provides the required block, we test it directly. Conflicting confirmations or unexpected availability require investigation at the handovers. Together, we prepare positive and negative reference cases for your Proalpha installation and its actual data flows.

Frequently asked questions about Proalpha

Must the entire Proalpha ERP system be validated?

The scope aligns with the intended GxP usage. The starting point is processes and data whose errors could lead to quality-related consequences. Commercial functions may lie outside the scope, provided their boundaries are justified. Consider common master data, roles, and interfaces: a formally excluded function may still alter critical information.

Sources: [6]

Is Proalpha validated for medical devices?

The MedTech website describes a sector-wide offering with relevant functionalities. This does not constitute validation evidence for your specific installation. The German manufacturer's page explicitly highlights customer-specific validation of the actually performed processes. Therefore, verify the agreed functional scope, configuration, and appropriate supplier documentation. The requirements for medical devices are not automatically equivalent to pharmaceutical GMP standards.

Sources: [4] [5]

Is Proalpha ERP 9.5 the binding target version here?

No. Release 9.5 is a publicly documented reference version from the manufacturer's submission of June 2025. The version that is supported and which components can be operated together must be determined for your installation. Additionally, document maintenance status, enhancements, and interface version numbers; the release designation alone does not adequately describe the verified state.

Sources: [2] [6]

Is batch traceability sufficient for material release?

No. Traceability answers the question of where material originated and where it was used. An approval or blockage decision must additionally be effectively implemented along the intended work processes. For example, check partial samples, manual withdrawals, and delayed status transfers. These review questions pertain to your process; they do not assert any specific Proalpha standard setting.

Sources: [3] [6]

Which CAQ and MES connections fall within the scope?

Include the connections that transmit critical decisions or evidence. Particular relevance applies to test status, batch identity, consumption, and production batches used. Clarify the leading system, data significance, error detection, and retry mechanisms. The manufacturer's announcement for integration into Release 9.5 does not replace the specifications of the connection implemented by your organization.

Sources: [2] [6]

Are Audit Trail and electronic signature included in the standard?

The medical device websites list these features for the industry offering. From this, the scope of a general ERP license cannot be reliably inferred. Confirm components, versions, rights, and configuration, and verify the intended effect. Following this, for Part 11, the specific regulatory requirements for recordkeeping and electronic signatures must be determined.

Sources: [4] [5] [7]

What documentation does a small company need?

Start with intended use, process and system overview, critical data, requirements, and responsibilities. From this, a justified risk assessment and appropriate validation evidence emerge. Configuration status, results, deviation decisions, and batch release are integrated. The value lies in traceable decisions, not in the creation of as many documents as possible with different titles.

Sources: [6]

Can the Proalpha partner perform the entire validation?

A partner may support specifications, configuration, and testing. Technical requirements, acceptance, and operational responsibility must remain clearly assigned within your organization. Agree on which documents the partner provides, for which version they apply, and who will address deviations. Verify that accepted evidence is actually used in practice.

Sources: [6]

How can the effort be estimated without fixed prices?

First, identify the critical process chains, interfaces, enhancements, and migration cases. Then assess the need for clarification and existing validation evidence. Plan separate internal departmental timelines as well as corrections and revalidation checks. This project structure enables a justified estimation; user count or license cost alone are insufficient for this purpose.

Sources: [6]

Must every update be revalidated?

The testing requirement follows changes and their impact on the released state. A relevant status transition may affect multiple systems; isolated changes may be assessed more closely. Document the rationale, selected tests, and release decisions. Include known defects and past outages, rather than automatically repeating the same full package.

Sources: [6]

Sources and review date

As of October 6, 2026. Product information is based on the officially listed Proalpha website pages. Release 9.5 is a documented reference version and does not imply anything about the latest build or your installation. MedTech-Suite features do not apply universally to standard ERP or Pharma systems. Regulatory reference case is the GMP application in human medicinal products; tables, checklists, and test cases are standalone planning aids.

  1. Proalpha: ERP system for the mid-market segment
  2. Proalpha: ERP-Release 9.5, 25 June 2025
  3. Proalpha: Sales, Marketing, and Service
  4. Proalpha: ERP for medical devices
  5. Proalpha: Business Application Suite for Medical Technology
  6. European Commission: EU GMP Annex 11, January 2011 revision
  7. FDA: Part 11 – Electronic Records; Electronic Signatures, Scope and Application

Sources checked: .

Daniel Herrmann, Daniel Herrmann Consulting

Daniel Herrmann Consulting

Define the relevant Proalpha scope jointly.

We support you in aligning process decisions, system boundaries, and evidence into a practical validation scope. Daniel Herrmann Consulting builds upon your existing installation and available documentation.

  • Computer system validation →

    Bring your GxP systems into validated operation, from laboratory software, MES and eQMS to ERP. We define the scope, plan risk-based tests using GAMP 5 and hand the evidence to QA for release.

Send a project enquiry Customer testimonials →